Sve nije tacno?daddy-kool wrote: ↑14/12/2020 14:16Ova priča nije tačna.Haris.ba wrote: ↑14/12/2020 12:51
Slusao sam na n1 intervju one doktorice iz Srbije sto je radila sa variola verom. Prica da Rusi imaju i trajnu vakcinu, ali da treba jos 3 - 4 godine testiranja. Ova Sputnik je valjda sa mrtvim virusom, valjda zato i 2 godine trajanje, a ova trajna je sa zivim virusom.
Corona cjepivo/vakcina - News
Moderator: O'zone
- Haris.ba
- Posts: 34740
- Joined: 08/09/2005 20:08
#1501 Re: Corona cjepivo/vakcina - News
-
daddy-kool
- Posts: 12709
- Joined: 30/07/2012 12:45
- Location: muslimansko ostrvo
#1502 Re: Corona cjepivo/vakcina - News
'Pretty high' chance of Oxford vaccine being rolled out before end of year, says lead scientist
https://www.telegraph.co.uk/global-heal ... sts-cases/
https://www.telegraph.co.uk/global-heal ... sts-cases/
-
Milenkov buraz
- Posts: 6956
- Joined: 27/11/2018 13:02
#1503 Re: Corona cjepivo/vakcina - News
Ja, i...?
Srpska naučnica analizirala sastojke Fajzerove vakcine
Isidora Stanković je srpska naučnica iz Niša, doktorand biomedicinskih nauka koja trenutno radi u američkom "Weill Cornell Medicine" u Njujorku, objavila je svoju analizu Fajzerove vakcine.
BUKA PORTAL / 12. Decembar 2020
Weill Cornell Medicine" je organizacija koja se bavi naučnim istraživanjima i najnovijim inovacijama u liječenju i prevenciji pacijenata od brojnih bolesti, a Isidora koja je trenutno tamo zaposlena detaljno je raščlanila sastav vakcine koju su razvile kompanije Fajzer i Biontek.
"Reših da iskoristim svoju diplomu biohemije i otkrijem šta je zaista u Pfizer RNK vakcini. Ne dajte da vas lažu, čitajte do kraja!
• BNT162b2 iRNK - modifikovani RNK spajk (S) proteina virusa korona, ovde pod nazivom BNT162b2
. • Polietilen glikol (PEG) - molekul koji se nalazi u brdo prirodnih proizvoda i milijardu lekova. Koristi se i u laksativima ili npr. da omekša sladoled (onaj na točenje). Ovde je u grupi masti.
• ALC-0315 = (4-hidroksibutil) azanedil)bis (heksan-6,1-dil)bis(2-heksildekanoat) ; ALC-0159 = 2-[(polietilen glikol)-2000]-N,N-ditetradecilacetamid; 1,2-Distariol-sn-glicero-3-fosfoholin holesterol. OVO SU MASTI.
Prave lipidni mehur oko RNK molekula i tako ga štite od razgradnje.
• Kalcijum hlorid, kalcijum-dihidrogen-fosfat, natrijum hlorid, dinatrijum-hidrogen-fosfat-dihidrat. OVO SU SOLI.
Prave koncentraciju jona u mehuru povoljnom.
• Sukroza - ŠEĆER. Radi isto što i soli. Ako koncentracija šećera i soli nije optimalna RNK se lako razgrađuje. • Dihidrogen monooksid - VODA. Rastvarač.
Poruka priče: Nije sve što zvuči 'opasno' jer smo bežali s časova hemije zaista i opasno. Poruka priče 2: Ova vakcina je toliko prirodna i organska da možete bakin kolač od nje da napravite."
-
daddy-kool
- Posts: 12709
- Joined: 30/07/2012 12:45
- Location: muslimansko ostrvo
#1504 Re: Corona cjepivo/vakcina - News
Nije tačno:Haris.ba wrote: ↑14/12/2020 18:11Sve nije tacno?daddy-kool wrote: ↑14/12/2020 14:16Ova priča nije tačna.Haris.ba wrote: ↑14/12/2020 12:51
Slusao sam na n1 intervju one doktorice iz Srbije sto je radila sa variola verom. Prica da Rusi imaju i trajnu vakcinu, ali da treba jos 3 - 4 godine testiranja. Ova Sputnik je valjda sa mrtvim virusom, valjda zato i 2 godine trajanje, a ova trajna je sa zivim virusom.
Da iko od njih zna koliko traje zaštita od koje vakcine.
Da imaju trajnu vakcinu.
Da Sputnik V koristi mrtvi virus - koristi kombinaciju 2 modifikovana virusna vektora da izazove imuni odgovor na "spike protein".
Sinopharm (kineska kompanija) je završila (ili završava) testiranje vakcine sa inaktiviranim virusom - ovo je starinski metod.
Živi (nemodifikovani) virus se ne koristi za vakcinaciju.
edit: Možda je mislina na atenuiranu vakcinu, ali ja nisam nigdje pročitao da se idu u tom smjeru... Ovdje je ograda sa moje strane..
Last edited by daddy-kool on 14/12/2020 18:29, edited 2 times in total.
-
Naslovnica
- Posts: 35074
- Joined: 20/03/2013 15:38
#1505 Re: Corona cjepivo/vakcina - News
Rahmetli nana je redovno solila meso prije pečenja sa "kalcijum-dihidrogen-fosfat idinatrijum-hidrogen-fosfat-dihidrat", a prije toga bi ga malo namastila i podmazala tepsiju sa "ALC-0315 = (4-hidroksibutil) azanedil)bis (heksan-6,1-dil)bis(2-heksildekanoat) ; ALC-0159 = 2-[(polietilen glikol)-2000]-N,N-ditetradecilacetamid; 1,2-Distariol-sn-glicero-3-fosfoholin holesterolom".

-
Mogy87
- Posts: 5966
- Joined: 27/05/2013 10:49
#1506 Re: Corona cjepivo/vakcina - News
Postavljala ja na prosloj stranici, kazu neozbiljna je sto se oglasava na facebooku.Milenkov buraz wrote: ↑14/12/2020 18:19 Ja, i...?![]()
Srpska naučnica analizirala sastojke Fajzerove vakcine
Isidora Stanković je srpska naučnica iz Niša, doktorand biomedicinskih nauka koja trenutno radi u američkom "Weill Cornell Medicine" u Njujorku, objavila je svoju analizu Fajzerove vakcine.
BUKA PORTAL / 12. Decembar 2020
Weill Cornell Medicine" je organizacija koja se bavi naučnim istraživanjima i najnovijim inovacijama u liječenju i prevenciji pacijenata od brojnih bolesti, a Isidora koja je trenutno tamo zaposlena detaljno je raščlanila sastav vakcine koju su razvile kompanije Fajzer i Biontek.
"Reših da iskoristim svoju diplomu biohemije i otkrijem šta je zaista u Pfizer RNK vakcini. Ne dajte da vas lažu, čitajte do kraja!
• BNT162b2 iRNK - modifikovani RNK spajk (S) proteina virusa korona, ovde pod nazivom BNT162b2
. • Polietilen glikol (PEG) - molekul koji se nalazi u brdo prirodnih proizvoda i milijardu lekova. Koristi se i u laksativima ili npr. da omekša sladoled (onaj na točenje). Ovde je u grupi masti.
• ALC-0315 = (4-hidroksibutil) azanedil)bis (heksan-6,1-dil)bis(2-heksildekanoat) ; ALC-0159 = 2-[(polietilen glikol)-2000]-N,N-ditetradecilacetamid; 1,2-Distariol-sn-glicero-3-fosfoholin holesterol. OVO SU MASTI.
Prave lipidni mehur oko RNK molekula i tako ga štite od razgradnje.
• Kalcijum hlorid, kalcijum-dihidrogen-fosfat, natrijum hlorid, dinatrijum-hidrogen-fosfat-dihidrat. OVO SU SOLI.
Prave koncentraciju jona u mehuru povoljnom.
• Sukroza - ŠEĆER. Radi isto što i soli. Ako koncentracija šećera i soli nije optimalna RNK se lako razgrađuje. • Dihidrogen monooksid - VODA. Rastvarač.
Poruka priče: Nije sve što zvuči 'opasno' jer smo bežali s časova hemije zaista i opasno. Poruka priče 2: Ova vakcina je toliko prirodna i organska da možete bakin kolač od nje da napravite."
-
Naslovnica
- Posts: 35074
- Joined: 20/03/2013 15:38
#1507 Re: Corona cjepivo/vakcina - News
Šta kažu, znaju li koliko traje zaštita kada se primi Pfizer vakcina?daddy-kool wrote: ↑14/12/2020 18:21Nije tačno:
Da iko od njih zna koliko traje zaštita od koje vakcine.
Da imaju trajnu vakcinu.
Da Sputnik V koristi mrtvi virus - koristi kombinaciju 2 modifikovana virusna vektora da izazove imuni odgovor na "spike protein".
Sinopharm (kineska kompanija) je završila (ili završava) testiranje vakcine sa inaktiviranim virusom - ovo je starinski metod.
Živi (nemodifikovani) virus se ne koristi za vakcinaciju.
edit: Možda je mislina na atenuiranu vakcinu, ali ja nisam nigdje pročitao da se idu u tom smjeru... Ovdje je ograda sa moje strane..
-
daddy-kool
- Posts: 12709
- Joined: 30/07/2012 12:45
- Location: muslimansko ostrvo
#1508 Re: Corona cjepivo/vakcina - News
Ne znaju ni koliko traje zaštita nakon prebolovane bolesti.Naslovnica wrote: ↑14/12/2020 18:33 Šta kažu, znaju li koliko traje zaštita kada se primi Pfizer vakcina?
![]()
-
Naslovnica
- Posts: 35074
- Joined: 20/03/2013 15:38
#1509 Re: Corona cjepivo/vakcina - News
daddy-kool wrote: ↑14/12/2020 18:42Ne znaju ni koliko traje zaštita nakon prebolovane bolesti.Naslovnica wrote: ↑14/12/2020 18:33 Šta kažu, znaju li koliko traje zaštita kada se primi Pfizer vakcina?
![]()
-
laik1981
- Posts: 14850
- Joined: 05/12/2012 13:04
#1510 Re: Corona cjepivo/vakcina - News
A ima li sta da znaju osim da cemo i narednu godinu morati nositi maske i uvoditi kojekakve mjere?
Ne znaju da li osobe sa antitijelima mogu prenositi virus ili ne mogu
Haj za vakcine je jos rano, ali i tu su imali desetine hiljada dobrovoljaca na kojima su ih testirali.. Nemoguce da ne znaju da li je neko od dobrovoljaca koji je vakcinisan zarazio nekog ili nije..
Ne znaju da li osobe sa antitijelima mogu prenositi virus ili ne mogu
Haj za vakcine je jos rano, ali i tu su imali desetine hiljada dobrovoljaca na kojima su ih testirali.. Nemoguce da ne znaju da li je neko od dobrovoljaca koji je vakcinisan zarazio nekog ili nije..
-
Bobi
- Forum administrator
- Posts: 37775
- Joined: 30/10/2002 00:00
- Location: http://www.klix.ba
- Grijem se na: J.P."Grijanje"Zenica
- Vozim: TDI sve crveno
- Contact:
#1511 Re: Corona cjepivo/vakcina - News
Jučer sam među prvima u BiH primio ono rusko cjepivo и за сада се чини на нема неких посебних нуспојава!
цјепиво је скроз харашо!
цјепиво је скроз харашо!
-
allem_77
- Posts: 3422
- Joined: 17/09/2015 15:46
#1512 Re: Corona cjepivo/vakcina - News
Imaš li djece? I vjeruješ li Dodiku? On kaže da ćemo možda biti jalovi.
-
daddy-kool
- Posts: 12709
- Joined: 30/07/2012 12:45
- Location: muslimansko ostrvo
#1513 Re: Corona cjepivo/vakcina - News
Postoje određene indicije.laik1981 wrote: ↑14/12/2020 19:11 A ima li sta da znaju osim da cemo i narednu godinu morati nositi maske i uvoditi kojekakve mjere?
Ne znaju da li osobe sa antitijelima mogu prenositi virus ili ne mogu![]()
Haj za vakcine je jos rano, ali i tu su imali desetine hiljada dobrovoljaca na kojima su ih testirali.. Nemoguce da ne znaju da li je neko od dobrovoljaca koji je vakcinisan zarazio nekog ili nije..
Kada je oxfordski tim radio ispitivanje vakcine na makaki majmunima, nakon vakcine su ih namjerno zarazili da bi vidjeli šta se dešava. Svi su razvili određene simptome i bolest, ali nisu imali upale pluća. To bi značilo da vakcina štiti od teškog oblika bolesti, ali da se vakcinisani mogu razboliti (ili biti asimptomatski) i širiti virus.
https://www.nature.com/articles/d41586-020-01092-3
Tests of other fast-tracked vaccines show that they have prevented infections in the lungs of monkeys exposed to SARS-CoV-2 — but not in some other parts of the body. One — a vaccine being developed at the University of Oxford, UK, that is also in human trials — protected six monkeys from pneumonia, but the animals’ noses harboured as much virus as did those of unvaccinated monkeys, researchers reported1 last week in a bioRxiv preprint. A Chinese group reported similar caveats about its own vaccine’s early animal tests this month2.
-
laik1981
- Posts: 14850
- Joined: 05/12/2012 13:04
#1514 Re: Corona cjepivo/vakcina - News
Clanak iz maja i od tada nista, a prosli sve faze testiranjadaddy-kool wrote: ↑14/12/2020 20:04Postoje određene indicije.laik1981 wrote: ↑14/12/2020 19:11 A ima li sta da znaju osim da cemo i narednu godinu morati nositi maske i uvoditi kojekakve mjere?
Ne znaju da li osobe sa antitijelima mogu prenositi virus ili ne mogu![]()
Haj za vakcine je jos rano, ali i tu su imali desetine hiljada dobrovoljaca na kojima su ih testirali.. Nemoguce da ne znaju da li je neko od dobrovoljaca koji je vakcinisan zarazio nekog ili nije..
Kada je oxfordski tim radio ispitivanje vakcine na makaki majmunima, nakon vakcine su ih namjerno zarazili da bi vidjeli šta se dešava. Svi su razvili određene simptome i bolest, ali nisu imali upale pluća. To bi značilo da vakcina štiti od teškog oblika bolesti, ali da se vakcinisani mogu razboliti (ili biti asimptomatski) i širiti virus.
https://www.nature.com/articles/d41586-020-01092-3
Tests of other fast-tracked vaccines show that they have prevented infections in the lungs of monkeys exposed to SARS-CoV-2 — but not in some other parts of the body. One — a vaccine being developed at the University of Oxford, UK, that is also in human trials — protected six monkeys from pneumonia, but the animals’ noses harboured as much virus as did those of unvaccinated monkeys, researchers reported1 last week in a bioRxiv preprint. A Chinese group reported similar caveats about its own vaccine’s early animal tests this month2.
Po ovom vakcina stiti od pneumonije, bar je majmune zastitila, a ne od ostalih komplikacija, kao sto su, npr., komplikacije izazvane ugruscima, ili bar ovdje nisu naveli te podatke..
Onda dalje stoji
Jel ovo znaci da se kod ovih 20 nisu razvila antitijela? Da li vakcina u pravilu treba da proizvede antitijela?In its press release, the company reported that 45 study participants who received one or two doses of the vaccine developed a strong immune response to the virus. Researchers measured virus-recognizing antibodies in 25 participants, and detected levels similar to or higher than those found in the blood of people who have recovered from COVID-19.
Porazavajuce je da je ovako malo dostupnih podataka o nekim krucijalnim pitanjima.. Desetine hiljada ljudi ucestvovalo u ispitivanjima, a opet ne znaju nista ili ne zele da otkriju..
-
vatreni__poljubac
- Posts: 334
- Joined: 02/12/2020 14:12
#1515 Re: Corona cjepivo/vakcina - News
U UK novi soj virusa ceka se prvi patch.
- Gusar-from-Riga
- Posts: 622
- Joined: 11/06/2020 18:04
#1516 Re: Corona cjepivo/vakcina - News
Ide nova vakcina sta ste se prepali

- spinel_
- Posts: 6633
- Joined: 15/11/2013 02:33
- Haris.ba
- Posts: 34740
- Joined: 08/09/2005 20:08
#1518 Re: Corona cjepivo/vakcina - News
Stoun je stari kontras. A, ne bi me cudilo i da je cvakno koju lovu, ili kako to zna biti u Rusiji dozvolu da uradi nesta sto je htio.
- DEMONIKA
- Posts: 3542
- Joined: 06/03/2016 02:35
#1519 Re: Corona cjepivo/vakcina - News
Stoun je Tito, e odoh reprizirati Platoon, JFK, The Untold History, Intervjue s Putinom, The People vs. Larry Flynt, Killer i NBK.... fala
-
Trappist
- Posts: 5998
- Joined: 12/09/2020 08:52
#1520 Re: Corona cjepivo/vakcina - News
https://www.index.hr/vijesti/clanak/ank ... 38952.aspx
"Anketa u bolnicama: Cijepljenje će odbiti 50% liječnika i 40% medicinskih sestara"
E jebiga, ako doktori odbijaju da se vakcinisu, kako ce tek onda narod reagovati
"Anketa u bolnicama: Cijepljenje će odbiti 50% liječnika i 40% medicinskih sestara"
E jebiga, ako doktori odbijaju da se vakcinisu, kako ce tek onda narod reagovati
-
Mogy87
- Posts: 5966
- Joined: 27/05/2013 10:49
#1521 Re: Corona cjepivo/vakcina - News
Moderna FDA review
Zasjedaju u petak, na osnovu materijala je izvjesno da ce dati odobrenje
The EUA request includes safety and efficacy data from an ongoing Phase 3 randomized, double-blinded and placebo-controlled trial of mRNA-1273 in approximately 30,400 participants. The primary efficacy endpoint is the reduction of incidence of COVID-19 among participants without evidence of SARS-CoV-2 infection before the first dose of vaccine in the period after 14 days post-dose 2. In an interim analysis conducted using a data cutoff of November 7, 2020, a total of 27,817 participants randomized 1:1 to vaccine or placebo with a median 7 weeks of follow-up post-dose 2 were included in the per-protocol efficacy analysis population of participants without evidence of SARS-CoV-2 infection prior to vaccination. Efficacy in preventing confirmed COVID-19 occurring at least 14 days after the second dose of vaccine was 94.5.0% (95% CI 86.5%, 97.8%) with 5 COVID-19 cases in the vaccine group and 90 COVID-19 cases in the placebo group. Subgroup analyses of the primary efficacy endpoint showed similar efficacy point estimates across age groups, genders, racial and ethnic groups, and participants with medical comorbidities associated with high risk of severe COVID-19. Secondary efficacy analyses suggested benefit of the vaccine in preventing severe COVID-19 (11 protocol-defined severe COVID-19 cases in the placebo group vs. 0 cases in the vaccine group), in preventing COVID-19 following the first dose, and in preventing COVID-19 in individuals with prior SARS-CoV-2 infection, although available data for some of these outcomes did not allow for firm conclusions. Efficacy data from the final scheduled analysis of the primary efficacy endpoint (data cutoff of November 21, 2020, with a median follow-up of >2 months post-dose 2) demonstrated a VE of 94.1% (95% CI 89.3%, 96.8%), with 11 COVID-19 cases in the vaccine group and 185 COVID-19 cases in the placebo group and was consistent with results obtained from the interim analysis. The VE in this analysis when stratified by age group was 95.6% (95% CI: 90.6%, 97.9%) for participants 18 to <65 years of age and 86.4% (95% CI: 61.4%, 95.5%) for participants ≥65 years of age. A final secondary efficacy analysis also supported efficacy against protocol-defined severe COVID-19, with 30 cases in the placebo group vs. 0 cases in the vaccine group.
Safety data from a November 11, 2020 interim analysis of approximately 30,350 participants ≥18 years of age randomized 1:1 to vaccine or placebo with a median of 7 weeks of follow-up after the second dose supported a favorable safety profile, with no specific safety concerns identified that would preclude issuance of an EUA. These safety data are the primary basis of FDA’s safety review. On December 7, 2020, the Sponsor submitted additional follow-up data from these participants with a cutoff of November 25, 2020, which represents a median of 9 weeks (>2 months) of follow-up post-dose 2. Key safety data from this later submission, including death, other serious adverse events, and unsolicited adverse events of interest were independently verified and confirmed not to change the safety conclusions from the interim safety analysis.
https://www.fda.gov/media/144434/download
Zasjedaju u petak, na osnovu materijala je izvjesno da ce dati odobrenje
The EUA request includes safety and efficacy data from an ongoing Phase 3 randomized, double-blinded and placebo-controlled trial of mRNA-1273 in approximately 30,400 participants. The primary efficacy endpoint is the reduction of incidence of COVID-19 among participants without evidence of SARS-CoV-2 infection before the first dose of vaccine in the period after 14 days post-dose 2. In an interim analysis conducted using a data cutoff of November 7, 2020, a total of 27,817 participants randomized 1:1 to vaccine or placebo with a median 7 weeks of follow-up post-dose 2 were included in the per-protocol efficacy analysis population of participants without evidence of SARS-CoV-2 infection prior to vaccination. Efficacy in preventing confirmed COVID-19 occurring at least 14 days after the second dose of vaccine was 94.5.0% (95% CI 86.5%, 97.8%) with 5 COVID-19 cases in the vaccine group and 90 COVID-19 cases in the placebo group. Subgroup analyses of the primary efficacy endpoint showed similar efficacy point estimates across age groups, genders, racial and ethnic groups, and participants with medical comorbidities associated with high risk of severe COVID-19. Secondary efficacy analyses suggested benefit of the vaccine in preventing severe COVID-19 (11 protocol-defined severe COVID-19 cases in the placebo group vs. 0 cases in the vaccine group), in preventing COVID-19 following the first dose, and in preventing COVID-19 in individuals with prior SARS-CoV-2 infection, although available data for some of these outcomes did not allow for firm conclusions. Efficacy data from the final scheduled analysis of the primary efficacy endpoint (data cutoff of November 21, 2020, with a median follow-up of >2 months post-dose 2) demonstrated a VE of 94.1% (95% CI 89.3%, 96.8%), with 11 COVID-19 cases in the vaccine group and 185 COVID-19 cases in the placebo group and was consistent with results obtained from the interim analysis. The VE in this analysis when stratified by age group was 95.6% (95% CI: 90.6%, 97.9%) for participants 18 to <65 years of age and 86.4% (95% CI: 61.4%, 95.5%) for participants ≥65 years of age. A final secondary efficacy analysis also supported efficacy against protocol-defined severe COVID-19, with 30 cases in the placebo group vs. 0 cases in the vaccine group.
Safety data from a November 11, 2020 interim analysis of approximately 30,350 participants ≥18 years of age randomized 1:1 to vaccine or placebo with a median of 7 weeks of follow-up after the second dose supported a favorable safety profile, with no specific safety concerns identified that would preclude issuance of an EUA. These safety data are the primary basis of FDA’s safety review. On December 7, 2020, the Sponsor submitted additional follow-up data from these participants with a cutoff of November 25, 2020, which represents a median of 9 weeks (>2 months) of follow-up post-dose 2. Key safety data from this later submission, including death, other serious adverse events, and unsolicited adverse events of interest were independently verified and confirmed not to change the safety conclusions from the interim safety analysis.
https://www.fda.gov/media/144434/download
-
vatreni__poljubac
- Posts: 334
- Joined: 02/12/2020 14:12
#1522 Re: Corona cjepivo/vakcina - News
doktoriTrappist wrote: ↑15/12/2020 10:06 https://www.index.hr/vijesti/clanak/ank ... 38952.aspx
"Anketa u bolnicama: Cijepljenje će odbiti 50% liječnika i 40% medicinskih sestara"
E jebiga, ako doktori odbijaju da se vakcinisu, kako ce tek onda narod reagovati![]()
- Haris.ba
- Posts: 34740
- Joined: 08/09/2005 20:08
#1523 Re: Corona cjepivo/vakcina - News
A ima li starosna struktura doktora koji bi se vakcinisali, a koji ne bi? Ako bi se vakcinisali stariji, bolesni i oni koji rade sa inficiranim sasvim dovoljno.
-
daddy-kool
- Posts: 12709
- Joined: 30/07/2012 12:45
- Location: muslimansko ostrvo
#1524 Re: Corona cjepivo/vakcina - News
Trappist wrote: ↑15/12/2020 10:06 https://www.index.hr/vijesti/clanak/ank ... 38952.aspx
"Anketa u bolnicama: Cijepljenje će odbiti 50% liječnika i 40% medicinskih sestara"
E jebiga, ako doktori odbijaju da se vakcinisu, kako ce tek onda narod reagovati![]()
To znači da će vakcina biti ranije dostupna onim koji se žele vakcinisati.
- pojedinac
- Posts: 1490
- Joined: 02/06/2006 19:02
- Contact:
